- Home
- CYAB vs APM Comparison
CYAB vs APM Comparison
Compare CYAB & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CYAB | APM |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 7.3M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | CYAB | APM |
|---|---|---|
| Price | $0.51 | $0.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 210.5K | ★ 255.6K |
| Earning Date | 04-09-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $0.65 |
| 52 Week High | $2.99 | $4.47 |
Technical Indicators
Market Signals| Indicator | CYAB | APM |
|---|---|---|
| Relative Strength Index (RSI) | 32.34 | 43.86 |
| Support Level | $0.46 | $0.74 |
| Resistance Level | $0.62 | $0.93 |
| Average True Range (ATR) | 0.06 | 0.16 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 19.81 | 3.81 |
Price Performance
Historical ComparisonAbout CYAB Cyabra Inc. Common Stock
Cyabra Inc is an AI-powered SaaS company that detects and analyzes online disinformation. Its platform uses machine learning to monitor social media and news data in real time, identify fake accounts and harmful narratives, and assess content authenticity and sentiment.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA). Substantially all of the company's revenues are derived from within Hong Kong.